First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness
Comparative Effectiveness of Haloperidol and SGAs for Treating Schizophrenia: Positive Symptoms
Haloperidol and second-generation antipsychotic s(SGAs) were compared for effectiveness in treating positive symptoms of schizophrenia. The assessment instruments commonly used were the Positive and Negative Syndrome Scale (PANSS) and the Scale for Assessment of Positive Symptoms (SAPS).
No statistically significant difference in effect was noted using the PANSS in studies that compared haloperidol with olanzapine (14 randomized controlled trials [RCTs]), quetiapine (4 RCTs), risperidone (20 RCTs), or clozapine (2 RCTs). No statistically significant difference in effect was noted using the SAPS in studies that compared haloperidol with olanzapine and risperidone (2 RCTs). The strength of evidence is low for each of these findings.
- Abou-Setta AM, Mousavi SS, Spooner C, et al. First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness. Comparative Effectiveness Review No. 63 (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021). Rockville, MD: Agency for Healthcare Research and Quality; August 2012. AHRQ Publication No. 12-EHC054-EF. Available at www.effectivehealthcare.ahrq.gov/antipsychotics-adult.cfm.
Your slide tray is being processed.